Quent Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Quent Capital’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56K	Sell	4,232 -33	-0.8%	-$22	﹤0.01%	1444
2026 Q1	$3.84K	Buy	4,265 +3,340	+361%	+$2.7K	﹤0.01%	1317
2025 Q4	$719	Buy	925 +817	+756%	+$1.02K	﹤0.01%	1492
2025 Q3	$134	Buy	+108	New	+$151	﹤0.01%	1403
2025 Q2	–	Sell	-108	Closed	-$161	–	498
2025 Q1	$161	Hold	108	–	–	﹤0.01%	1288
2024 Q4	$432	Sell	108 -2	-2%	-$13	﹤0.01%	1278
2024 Q3	$1.38K	Hold	110	–	–	﹤0.01%	1253
2024 Q2	$1.61K	Hold	110	–	–	﹤0.01%	1236
2024 Q1	$2.47K	Hold	110	–	–	﹤0.01%	1206
2023 Q4	$2.08K	Buy	110 +4	+4%	+$76	﹤0.01%	1196
2023 Q3	$1.81K	Buy	106 +34	+47%	+$808	﹤0.01%	1188
2023 Q2	$2.17K	Buy	+72	New	+$2.37K	﹤0.01%	1176

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Quent Capital's CTXR Position: Q2 2026 in Review

Quent Capital reduced its Citius Pharmaceuticals (CTXR) stake by 0.77% in Q2 2026, selling an estimated $22 and leaving 4,232 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Quent Capital first reported a position in CTXR in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.84K in Q1 2026. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Quent Capital held 4,232 shares of Citius Pharmaceuticals worth $2.56K as of Q2 2026.
Quent Capital sold 33 Citius Pharmaceuticals shares in Q2 2026, an estimated $22.
Citius Pharmaceuticals made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1444 holding.
Quent Capital first reported a position in Citius Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Quent Capital's Citius Pharmaceuticals position peaked at $3.84K in Q1 2026.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.